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Rahul Mhaskar,1 Ambuj Kumar,1,4 Madhusmita Behera,1 Mohamed A. Kharfan-Dabaja,2,4
Benjamin Djulbegovic3,4Significant uncertainty exists regarding the efficacy of high-dose chemotherapy and autologous hematopoi-
etic cell transplantation (AHCT) for the treatment of patients with primary systemic (AL) amyloidosis. We
performed a systematic review and meta-analysis to evaluate the efficacy of AHCT versus conventional che-
motherapy (CC) in patients with AL amyloidosis using methodology recommended by the Cochrane Collab-
oration. A comprehensive literature search yielded 820 studies. Twelve studies met the inclusion criteria:
1 randomized controlled trial (RCT), 2 other controlled studies, and 9 single-arm trials. The 1 RCT and 2
controlled studies compared AHCTand CC, and 9 single-arm studies assessed the efficacy of AHCTwithout
a control. The pooled hazard ratio for overall survival (OS) in the 3 controlled studies was 1.79 (95% con-
fidence interval [CI]5 1.11 to 2.91) favoring CC. The pooled proportion for mortality in the single-arm stud-
ies (n 5 7) was 0.35 (95% CI 5 0.25 to 0.46). The pooled odds ratio for complete hematologic response
(CHR) from 2 controlled studies was 0.64 (95% CI 5 0.25 to 1.64), indicating no difference between
AHCT and CC. In the single-arm studies, the pooled proportion for CHR was 0.35 (95% CI 5 0.26 to
0.44), and the pooled proportion for treatment-related mortality (TRM) was 0.12 (95% CI 5 0.09 to
0.14). In the controlled studies, there was no heterogeneity for any outcome; however, in the single-arm
studies, there was a significant heterogeneity for the outcomes of OS, CHR, renal response, and partial he-
matologic response. Our findings indicate that AHCT does not appear to be superior to CC in improving OS
in patients with AL amyloidosis. But the quality of our evidence is low, indicating a need for well-designed and
adequately powered RCTs to better address the role of AHCT in AL amyloidosis.
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Primary systemic (AL) amyloidosis is a relatively
rare systemic disorder caused by deposition of proteins
derived from immunoglobulin light chain fragments in
various organs. The major organs involved are kid-
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6/j.bbmt.2009.01.022to significant dysfunction and poor prognosis in
patients with AL amyloidosis [1]. Once the diagnosis
of AL amyloidosis is established, prompt treatment is
indicated to prevent irreversible organ damage [2].
Treatment for AL amyloidosis is generally similar to
that for other plasma cell dyscrasias such as multiple
myeloma (MM), comprising mainly various chemo-
therapy combinations [3-5]. In addition, high-dose
melphalan (Mel) followed by autologous hematopoi-
etic cell transplantation (AHCT) has been increasingly
advocated as an effective treatment for patients with
AL amyloidosis [6]. The observed benefits of AHCT
in the treatment of myeloma provided a scientific ra-
tionale for evaluating a similar approach in the man-
agement of AL amyloidosis [7].
The efficacy of AHCT compared with conven-
tional chemotherapy (CC) in treating AL amyloidosis
is not known, however. Even though some studies
have shown better outcomes with AHCT, whether
these improved outcomes can be attributed to selection
bias or are a result of AHCTper se remains unclear [8].893
894 Biol Blood Marrow Transplant 15:893-902, 2009R. Mhaskar et al.To address this uncertainty, we performed a systematic
review to assess the efficacy of AHCT versus CC in
patients with AL amyloidosis. The primary goal of
this systematic review was to synthesize and critically
appraise the totality of the existing evidence on the
effects of AHCT in the management of AL
amyloidosis, which, to the best of our knowledge, has
not been done previously.METHODS
Literature Search
We searched the MEDLINE (PubMed) database
using a broad search strategy. Our search comprised
of 2 parts: methodological, aiming to locate random-
ized controlled trials (RCTs) [9], and specific, identify-
ing all prospective studies related to AL amyloidosis.
The studies were identified using a combination of
MeSH terms related to primary systemic AL amyloid-
osis and therapy, such as ‘‘amyloidosis’’ [MeSH] or
(‘‘AL’’ or ‘‘primary’’ or ‘‘systemic’’ or ‘‘light chain’’)
and ‘‘therapeutics’’ [MeSH] or ‘‘therapy’’ [subheading]
also ‘‘amyloidosis’’ [MeSH] and ‘‘clinical trial’’
[MeSH] as publication type or clinical trial as topic.
The search for single-arm prospective trials was lim-
ited to January 2001 through March 2008; however,
the search for RCTs was performed from January
1966 to March 2008. Meeting abstracts from the
American Society of Hematology (ASH), European
Society of Hematology, and American Society of Clin-
ical Oncology (ASCO) were hand-searched for the
years 2001-2008.Inclusion Criteria
An RCT was included if it evaluated the efficacy of
AHCT versus CC and enrolled at least 10 patients in
each arm. Nonrandomized single-arm prospective tri-
als with or without historical controls also were
included. A study was deemed eligible if it assessed at
least one of the following outcomes: overall survival
(OS), event-free survival (EFS), hematologic response
(complete [CHR] or partial [PHR]), renal response,
treatment-related morbidity, and treatment-related
mortality (TRM). Retrospective studies were
excluded.Study Selection, Quality Assessment, and Data
Extraction
Two reviewers (R.M. and M.B.) appraised the list
of references and selected the studies in consultation
with 2 other reviewers (B.D. and A.K.). Disagreements
were resolved by consensus. Three reviewers (R.M.,
M.B., and M.K.D.) independently extracted the data
from selected articles. Data were extracted on selectedclinical outcomes (benefits and harms), as well as on
the methodological quality of the trials.
Data Analysis and Statistical Methods
Trials with active control (RCTs and non-RCTs)
Time-to-event data and dichotomous data were
pooled and reported using a random-effects model.
When time-to-event data were not available for direct
extraction, the hazard ratio (HR) was assessed indirectly
according to themethod described by Parmar et al. [10].
Single-arm trials (studies without control)
For the purpose of meta-analysis, the proportions
were transformed into a quantity according to the
Freeman-Tukey variant of the arcsine square root-
transformed proportion [11]. The pooled proportion
was calculated as a back-transform of the weighted
mean of the transformed proportions, using the ran-
dom-effects model.
A formal statistical test for heterogeneity was per-
formed using the I2 test [12]. Heterogeneity and the
robustness of the findings also were explored through
additional sensitivity analyses. The possibility of pub-
lication bias was investigated using the funnel plot
method of Begg and Mazumdar [13] and Egger et al
[14]. This method has its limitations, but nonetheless
is widely used to assess publication bias [15].
The meta-analysis was done using Stata, release 9
(StataCorp, College Station, TX). The work was per-
formed according to the guidelines published in the
Quality of Reporting ofMeta-Analyses statement [16].RESULTS
Identification of Studies
The process of identifying and selecting studies for
the systematic review is summarized in Figure 1. The
initial search yielded 820 references. From these, 46
were selected for further full text analysis, of which
12 trials met the final inclusion criteria and were
included in the final analysis (Figure 1). These 12 stud-
ies included 1 RCT [17], 2 two-arm non-RCTs (n5 2)
[18,19], and 9 single-arm trials (n 5 9) [20-28]. Note
that van Gameren et al. [19] reported data on 2 studies,
an RCTwith a historical control and a single-arm trial;
therefore, we cite this same reference for 2 separate
studies. All of the included studies were published as
full text. Characteristics of the 12 studies are summa-
rized in Table 1.
Methodological Quality of Studies
We conducted a critical appraisal of the methodo-
logical quality of all studies according to the GRADE
criteria [29].
Figure 1. Flow diagram showing the process of identifying and select-
ing relevant studies
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Themethodof randomizationwasnot reported, and
allocation concealment was inadequate in the RCT
reported by Jaccard et al. [17]; however, the RCT did
report a priori sample size calculations and adequately
described withdrawals and dropouts, and the data
were analyzed according to the intention-to-treat
principle [17].
Non-RCTs
Altogether, 11 studies were non-RCTs. Of the 2
studies with a control arm, 1 had an active comparator
[18] and the other used a historical control [19]. The re-
maining9 studieswere single-armtrials.All of these trials
but one [23] described withdrawals and dropouts; how-
ever,only3of the trials (33%) [21,22,27] reportedapriori
sample size calculations. None of the nonrandomized
studies reported a priori sample size calculations.
Study characteristics, including the eligibility cri-
teria of the patients enrolled in the studies, are summa-
rized in Table 1. Overall, the methodological quality
of the studies was poor.
Publication Bias
Because there was only 1RCT [17], we did not assess
publicationbias forRCT.Theassessment forpublication
bias in the single-armtrials using theBeggandEgger fun-
nel plot for theoutcomesofOS,CHR, andTRMshoweda symmetric distribution, indicating no publication bias
(P5 .85 for OS, .98 for CHR, and .10 for TRM).Outcomes
OS
Trials with Active Control (RCTs and Non-
RCTs). The pooled results for OS did not favor
AHCT over CC. The pooled HR for OS in the 1
RCT and 2 non-RCTs was 1.79 (95% CI 5 1.11 to
2.91; P5 .018), indicating a statistically significant dif-
ference favoring CC (Figure 2). Similarly, the HR for
the outcome of OS in the RCT was 1.78 (95% CI 5
1.03 to 3.08; P 5 .04) favoring CC [18]; however, the
pooled results from the 2 non-RCTs [19,20] demon-
strated a statistically nonsignificant difference between
AHCT and CC (HR5 1.76; 95%CI5 0.53 to 5.84; P
5 .35). There was a statistically nonsignificant hetero-
geneity among the 3 studies (I25 0.00; P5 .51) for the
outcome of OS.
Single-Arm Trials (Studies without Control).
Data on OS were extractable from 78% (7/9) of the
single-arm trials. In the single-arm trials, the pooled
proportion of mortality was 0.35 (95% CI 5 0.25 to
0.46) (Figure 3); however, there was a statistically sig-
nificant heterogeneity for the outcome of OS
(I2 5 71.5%; P 5 .002).
CHR
Trials with Active Control (RCTs and Non-
RCTs). Data on CHR were extractable from the
RCT and 1 non-RCT [17,18]. The OR for CHR
was 0.64 (95% CI 5 0.25 to 1.64; P 5 .35), indicating
a statistically nonsignificant difference between
AHCT and CC (Figure 4). In addition, there was no
statistically significant heterogeneity in these trials
for the outcome of CHR (I2 5 0.00; P 5 .85).
Single-Arm Trials (Studies without Control).
Data on CHR were extractable from 89% of the stud-
ies (8/9). The pooled proportion of CHR was 0.35
(95%CI5 0.26 to 0.44) (Figure 5). There was a signif-
icant heterogeneity among studies for the outcome of
CHR, however (I2 5 74.3%; P 5 .00).
PHR
Trials with Active Control (RCTs and Non-
RCTs). The RCT [17] reported data only on PHR
and demonstrated no difference between AHCT and
CC. The OR was 0.35 (95% CI 5 0.06 to 2.10;
P 5 .25).
Single-Arm Trials (Studies without Control).
PHR was reported in 33% (3/9) of the single-arm
studies [19,21,26] and ranged from 8% [21] to 78%
[19]. The pooled proportion of PHR from the sin-
gle-arm trials was 0.34 (95%CI5 0.17 to 0.50). There
was a statistically significant heterogeneity among
these, however (I2 5 85.7%; P 5 .00).
Table 1. Characteristics of Included Studies
Author Patient Characteristics Intervention Comparison Primary Outcome
Number of Institutions
Involved Methodological Quality
Study design: RCT
Jaccard et al., 2007 [17] n5 100 (SCT, 50; M-Dex, 50)
Age: 58 (40-69) years
Male, n 5 57; female,
n 5 43
ECOG status: 0-2
IV HDM + ASCT Oral Mel + oral Dex
(M-Dex)
OS: HR 5 1.78
(95% CI 5 1.03 to 3.08)
Multicenter international a priori sample size
calculations: Yes
Randomization method: Not
reported
Allocation concealment: Not
adequate/unclear
Dropouts described: Yes
Intention-to-treat analysis:
Yes
Study design: Nonrandomized 2-arm RCT
Gono et al., 2004 [18] n 5 31
Age: 59.5 (44-78) years
Male, n 5 17; female,
n 5 14
SWOG status: 0-2
VAD + Mel + ASCT VAD OS: HR 5 0.80
(95% CI 5 0.14 to 4.61)
Single institution a priori sample size
calculations: No
Dropouts described: Yes
Intention-to-treat analysis:
No
Van Gameren et al., 2002 [19] n 5 18
Age: 53 (43-62)
Male, n 5 9; female,
n 5 9
SWOG status: 0-2
VAD + HDM + ASCT Mel + predisnone (MP)
(historical control)
OS: HR 5 2.83
(95% CI 5 0.82 to 9.77)
Single institution a priori sample size
calculations: No
Dropouts described: Yes
Intention-to-treat analysis:
Yes
Study design: Single arm without control
Gertz et al., 2004 [22] n 5 30
Age: 54 (42-71) years
Male, n 5 20; female,
n 5 8
ECOG status: 0-2
SCT+IV Mel
Mel:
Not applicable OS: Proportion 5 0.39
(95% CI 5 0.19 to 0.59)
Multicenter trial a priori sample size
calculations: Yes
Drop-outs described: Yes
Intention-to-treat analysis:
No (for response)
Gertz et al., 2002 [24] n 5 66
Age: 54 (31-70) years
Male, n 5 37; female,
n 5 29
SCT + IV Mel
Mel
Also, 17 patients received
Mel + total body irradiation
(12 Gy)
Not applicable OS: Proportion 5 0.21
(95% CI 5 0.11 to 0.32)
Single institution a priori sample size
calculations: No
Drop-outs described: No
Intention-to-treat analysis:
Yes
Blum et al., 2003 [20] n 5 13
Age: 56 (35-67) years
Male, n 5 8; female,
n 5 5
ECOG status: 0-2
Chemotherapy + peripheral
blood stem cell
transplantation + total body
irradiation +
ASCT
For chemotherapy,
Dex alone was
recommended, but other
regimens were permitted
including Mel/prednisone,
VAD, and VMCP
Not applicable OS: Proportion 5 0.54
(95% CI 5 0.23 to 0.85)
Single institution a priori sample size
calculations: No
Drop-outs described: Yes
Intention-to-treat analysis:
Unclear
8
9
6
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
5
:8
9
3
-9
0
2
,
2
0
0
9
R
.
M
h
a
sk
a
r
e
t
a
l.
Skinner et al., 2004 [28] n 5 394
Age: 56.9 (0-80) years
Male, n 5 232; female,
n 5 162
SWOG status: < 2
IV Mel + ASCT
Mel
Not applicable OS: Proportion 5 0.44
(95% CI 5 0.39 to 0.50)
Single institution a priori sample size
calculations: No
Drop-outs described: Yes
Intention-to-treat analysis:
Unclear
Perz et al., 2004 [26] n 5 28
Age: 54 (34-65), years
Male, n 5 19; female,
n 5 9
WHO status: 0-2
2-5 cycles of VAD followed by
HDM + ASCT
Not applicable OS: Proportion 5 0.29
(95% CI 5 0.10 to 0.47)
Single institution a priori sample size
calculations: No
Drop-outs described: Yes
Intention-to-treat analysis:
Unclear
Perfetti et al., 2006 [25] n 5 22
Age: 51 (31-65) years
Male, n 5 16; female,
n 5 6
ECOG status: 0-2
IV HDM + ASCT
Mel
Not applicable OS: Proportion 5 0.50
(95% CI 5 0.27 to 0.73)
Single institution a priori sample size
calculations: No
Drop-outs described: Yes
Intention-to-treat analysis:
Yes
Sanchorawala et al., 2007 [27] n 5 62
Age: 55.5 (32-65) years
Male, n 5 40; female,
n 5 22
SWOG status: < 2
HDM + SCT, 2 cycles Not applicable OS: Data not extractable.
CHR: Proportion 5 0.56
(95% CI 5 0.43 to 0.70)
Single institution a priori sample size
calculations: Yes
Drop-outs described: Yes
Intention-to-treat analysis:
Unclear
Cohen et al., 2007 [21] n5 45
Age: 57 (34-73) years
Male, n 5 23; female,
n 5 22
Mel + SCT
Mel followed by adjuvant
therapy with Dex + Thal
Not applicable OS: Proportion 5 0.24
(95% CI 5 0.11 to 0.38)
Single institution a priori sample size
calculations: Yes
Drop-outs described: Yes
Intention-to-treat analysis:
Yes
Gertz et al., 2007 [24] N 5 282
Age: 55-59 years
(median age not
extractable)
Data on males and
females enrolled
not extractable.
HDM + SCT Not applicable OS: Data not extractable.
CHR: Proportion 5 0.33
(95% CI 5 0.27 to 0.39)
Single institution a priori sample size
calculations: No
Drop-outs described: Yes
Intention-to-treat analysis:
Yes
Mel, melphalan; HDM, high-dose melphalan; Dex, dexamethasone; ASCT, autologous stem cell transplantation; VAD, vincristine + adriamycin + dexamethasone; Thal, thalidomide;
VMCP, vincristine + melphalan + cyclophosphamide + prednisone; SWOG, South West Oncology group; ECOG, Eastern Cooperative Oncology Group.
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Figure 2. Forest plot of OS with CC and AHCT versus CC for AL amyloidosis. The summary effect estimates (HR) for individual RCTs are indicated by
black rectangles, with the size of the rectangle proportional to the study weight; the lines represent 95% CIs. The overall summary effect estimates (HR)
and 95% CIs are indicated by the diamond.
898 Biol Blood Marrow Transplant 15:893-902, 2009R. Mhaskar et al.Renal response
Trials with Active Control (RCTs and Non-
RCTs). Renal response was reported in the RCT
[17]. The OR for renal response was 0.88 (95% CI 5
0.30 to 2.53; P5 .80), indicating no difference between
AHCT versus CC. Data on renal response were not
extractable from the 2 non-RCTs [18,19].
Single-Arm Trials (Studies without Control).
Data on renal response were extractable from 33%
(3/9) of the single-arm studies [21,26,30]; the renal
response ranged from 21% [30] to 50% [26]. TheFigure 3. Forest plot for proportion of deaths in CC andAHCT for AL amyloid
died by numberof patientswho received the treatment) for individual studies are
to the study weight; the lines represent 95% CIs. The overall summary effect epooled proportion of renal response was 0.34 (95%
CI5 0.15 to 0.52). There was a statistically significant
heterogeneity among the studies, however
(I2 5 70.8%; P 5 .03).
TRM
Trials with Active Control (RCTs and Non-
RCTs). The RCT [17] reported a TRM of 24%
(9/37) with the use of AHCT, compared with 0%
(0/43) with CC. The risk ratio for TRM was 22.0
(95% CI 5 1.324 to 365.5; P 5 .03), indicatingosis. The summary effect estimates (proportion: numberof patientswho
indicated by black rectangles, with the size of the rectangles proportional
stimate (proportion) and 95% CI are indicated by the diamond.
Figure 4. Forest plot of CHRwith CC and AHCT versus CC for AL amyloidosis. The summary effect estimates (OR) for individual RCTs are indicated
by black rectangles, with the size of the rectangles proportional to the study weight; the lines represent 95% CIs. The overall summary effect estimates
(OR) and 95% CIs are indicated by the diamond.
Biol Blood Marrow Transplant 15:893-902, 2009 899AHCT in Amyloidosis: A Systematic Reviewa statistically significant risk with the use of AHCT.
Data on TRM were not extractable from the other
controlled studies [18,19].
Single-Arm Trials (Studies without Control).
Data on TRM were extractable from 82% (9/11) of the
single-arm studies. The pooled proportion of TRM
withAHCTwas0.12 (95%CI5 0.09 to0.14) (Figure6).
There was no statistically significant heterogeneity
among the studies, however (I25 0.00; P value5 .56).Figure 5. Forest plot for proportion of CHR in CC and AHCT for AL amyloid
CHR by number of patients receiving the treatment) for individual studies are i
to the study weight; the lines represent 95% CIs. The overall summary effectTreatment-related morbidity
Trials with Active Control (RCT and Non-
RCTs). Data on treatment-related morbidity were
not reported in the RCT [17]. Infections resulting
from cytomegalovirus (CMV) or Pneumocystis carinii
occurred in 21% (3/14) of the patients on the AHCT
arm (compared with none in the CC arm) in the
non-RCT reported by Gono et al. [18]. In the study
reported by van Gameren et al. [19], 100% (12/12)osis. The summary effect estimates (proportion: number of patients with
ndicated by black rectangles, with the size of the rectangles proportional
estimate (proportion) and 95% CI are indicated by the diamond.
Figure 6. Forest plot for proportion of TRM in CC and AHCT for AL amyloidosis. The summary effect estimates (proportion: number of patients dying
from treatment- related causes by number of patients receiving the treatment) for individual studies are indicated by black rectangles, with the size of the
rectangles proportional to the study weight; the lines represent 95% CIs. The overall summary effect estimate (proportion) and 95% CI are indicated by
the diamond.
900 Biol Blood Marrow Transplant 15:893-902, 2009R. Mhaskar et al.of patients on the AHCT arm and 0% (0/9) of those on
the control arm experienced neutropenic fever and
mucositis.
Single-Arm Trials (Studies without Control).
In the single-arm trials, infection was the most com-
mon treatment-related morbidity (range, 14% to
63%) followed by gastrointestinal toxicity (range, 7%
to 66%). In the study reported by Perz et al. [26],
61% (24/38) of the patients experienced treatment-re-
lated toxicities of central nervous system, including
seizures. Acute renal failure occurred in 21% (37/
173) of the patients in the study reported by Fadia
et al. [30]. In the study reported by Sanchorawala
et al. [27], the tandem cycle of high-dose Mel and
AHCT was associated with bacterial sepsis syndrome.
This occurred more commonly after the second cycle
of Mel and AHCT than after the first cycle (12% vs
4%) [27].Sensitivity analyses
Single-Arm Trials (Studies without Control).
Additional sensitivity analyses were conducted to iden-
tify the reasons for the heterogeneity among the sin-
gle-arm trials for the outcomes of OS, CHR, PHR,
and renal response. For CHR, estimates in 3 studies
[19,21,24] were considered outliers, because the
results were outside the range of the pooled estimates.
Removing these outliers from the pooled analysis
resulted in the disappearance of a statistically signifi-
cant heterogeneity (I2 5 17.7%; P5 .30). The pooled
CHR after the removal of outliers was 0.45 (95%CI50.37 to 0.52). The reasons for the statistically signifi-
cant heterogeneity for OS, PHR, and renal response
among the single-arm studies could not be identified,
however.
Additional sensitivity analyses according to num-
ber of institutions involved in the study (multiple insti-
tutions vs single institution), treatment regimen
(eg, Mel vs vincristine1 adriamycin1 dexamethasone
[VAD]), renal status (patients with vs without impaired
renal function), or cooperative group scoring criteria
(SouthWest Oncology Group vs Eastern Cooperative
Oncology Group) used for inclusion did not change
any of our findings. A sensitivity analysis also was per-
formed to address the issues related to the occurrence
of zero count in individual studies and their inclusion
in the meta-analysis of single-arm trials. For the out-
come of CHR, the study of van Gameren et al. [19] re-
ported CHR in 0 of 9 patients.
We conducted 3 separate sensitivity analyses. In
the first analysis, we included the data from the study
of van Gameren et al. [19] in the meta-analysis accord-
ing to the reported number of events (ie, 0/9 patients);
the pooled estimate for CHR in single-arm trials was
0.34 (95% CI 5 0.18 to 0.49). In the second analysis,
we included the data from that study and used the con-
tinuity correction (0.5/9.5), resulting in a pooled CHR
estimate of 0.35 (95%CI5 0.26 to 044). Finally, in the
third analysis, we removed the data from that study
from the CHR meta-analysis, resulting in a pooled es-
timate of 0.39 (95%CI5 0.30 to 0.47). The pooled re-
sults for CHR reported here involve continuity
correction.
Biol Blood Marrow Transplant 15:893-902, 2009 901AHCT in Amyloidosis: A Systematic ReviewDISCUSSION
Our results demonstrate that systemic AL amy-
loidosis remains incurable with currently available
chemotherapy combinations such as Mel and predni-
sone [31], which are somewhat superior to placebo
[32] or colchicines [33]. Thus, evidence supports
a role for chemotherapy in altering the natural history
of AL amyloidosis. Prognosis remains poor, however,
with median survival ranging from 12 to 18 months,
even worse (4 to 6 months) with cardiac involvement.
In general, only\5% of patients with AL amyloidosis
survive 10 years or beyond [31].
Some studies have reported that a combination of
high-dose chemotherapy and AHCT is capable of
inducing clinical remissions and prolonging survival
in AL amyloidosis [34,35]; however, evidence from
our systematic review and meta-analysis demonstrates
no superiority of this treatment regimen in patients
with AL amyloidosis. In fact, as demonstrated in our
results from the 2-arm trials, CC was superior to
high-dose chemotherapy and AHCT in improving
OS (HR 5 1.79; 95% CI 5 1.11 to 2.91; P 5 .01).
These estimates might be biased, however, because
of high dropouts in the study reported by vanGameren
et al. [19], in which 6 of 18 patients refused to enroll in
the AHCT arm. But even after data from vanGameren
et al. were excluded, the difference in OS between CC
and AHCT was not statistically significant (HR 5
1.65; 95% CI 5 0.98 to 2.79; P 5 .06). Nevertheless,
the quality of evidence supporting this conclusion is
relatively poor, demonstrating the need for future
studies to investigate the role of AHCT in AL amy-
loidosis.
Our findings also indicate no difference in CHR
between AHCT and CC in the 2-arm trials (OR 5
0.64; 95% CI 5 0.25 to 1.64; P 5 .35); however, this
estimate might be biased, because of high TRM in
the AHCT arm [17]. Similarly, our analysis of hemato-
logic responses among the single-arm trials revealed
no superiority of AHCT over CC (Figure 5). Never-
theless, the pooled proportion of CHR obtained
from the single-arm trials is noteworthy (35%), likely
indicating the upper feasibility limits of efficacy in
selected patients.
As discussed in the discussion of the sensitivity
analyses, one limitation of our analysis is related to
the occurrence of zero counts in individual studies
and their inclusion in a meta-analysis of single-arm tri-
als. Many authors have addressed this issue by con-
ducting simulation studies [36,37] and recommend
conducting sensitivity analyses using several methods
and continuity correction factors [37], which we have
done here. In our 3 sensitivity analyses, the pooled
estimate for CHR (the only outcome with a zero
occurrence) for the single-arm studies was not
affected.One criteria for high-quality reporting is that data
be reported in a form that allow it to be extracted and
used in a quantitative research synthesis (ie, meta-
analysis). In most of the studies included in this sys-
tematic review, treatment-related morbidities were
not reported as events per patient and thus could not
be used in the meta-analysis. That is, treatment-
related morbidities were reported using statements
that did not allow us to distinguish between specific ad-
verse events occurring in multiple patients or multiple
events occurring in a single patient. Finally, as dis-
cussed earlier, the quality of evidence is low, with
only one small RCT (sample size n 5 100) and likely
selection bias in the non-RCTs.
In summary, our findings suggest that AHCT does
not appear to be superior to CC in improving survival
of patients with AL amyloidosis. One important limita-
tion of this meta-analysis is the relatively small number
of eligible studies, especially RCTs. Moreover, patients
with AL amyloidosis have significant comorbidities,
limiting their enrollment in clinical trials because of re-
strictive eligibility criteria. These limitations explain the
limited power of our analysis. For example, the only
RCT included in our systematic review enrolled a total
of 100 patients, but at least 340 patients (at a 5 0.05
and b 5 0.2) would be needed to detect a 15% survival
advantage. Our results underscore the urgent need for
well-designed RCTs with adequate power to address
the existing uncertainty related to determining the
most optimal treatment approach for AL amyloidosis.ACKNOWLEDGMENTS
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